This course is part of the P.A.C.T.: Practical Approaches to Comprehensive Treatment of Pain curriculum.
doctor with and on patients shoulder on left side

This course is part of the P.A.C.T.: Practical Approaches to Comprehensive Treatment of Pain curriculum.

Interactive Learning

1.00 CME Credit

Part 3: Approaches to Opioid Treatment and Counseling PatientsAn Interactive Learning Experience
This course is hosted by an external partner. By clicking Begin, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

Approaches to Opioid Treatment and Counseling Patients is Part 3 of the 3-part curriculum, P.A.C.T. Practical Approaches to Comprehensive Treatment of Pain, which examines the full spectrum of pain management options available to clinicians, including the safe and effective use of opioids.


In Part 3, you will learn strategies for developing individualized pain management plans, counseling patients who are prescribed opioids about safe and effective practices and identifying signs of opioid use disorder and its treatment.


This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://www.opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).


Each activity will cover various state-specific content and guidelines, also available for download.


Learners must complete three parts; Part 1: Assessing Pain and Initiating Non-Opioid Pain Management, Part 2: Reducing Risks with Opioid Use, and Part 3: Approaches to Opioid Treatment and Counseling Patients, in order to be a fully FDA Blueprint compliant completer

 

Begin

CME Information

1.00 AMA PRA Category 1 Credits™, 1.00 ABIM MOC or 1.11 AANP, including 0.69 AANP Pharm

Release Date: 11/30/2023

Expiration Date: 10/31/2024

Topics

Faculty

Learning Objectives

  • Identify risk factors and stratification for opioid-related aberrant behavior and opioid use disorder as part of the initial assessment
  • Review general characteristics of opioid analgesics including their intended use and risks
  • Select approaches to safely initiate opioids for the treatment of acute pain and chronic pain 
  • Identify strategies for ongoing safe and effective use of opioids in patients with chronic pain, including titration, referral, and discontinuation, when appropriate 
  • Summarize counseling strategies for caregivers and patients on opioid therapy
  • Act appropriately to evaluate, treat, or refer patients with opioid use disorder

 

State Licensure Requirements

This activity satisfies topic-specific CME/CE requirements (pain management, controlled substances, etc.) of many state licensing boards. Please check with your state’s licensing boards for specific requirements, and print this page as appropriate for documentation.

Iowa: This activity is designed to satisfy requirements of ARNPs, for CE regarding the US Centers for Disease Control and Prevention Guideline for prescribing opioids for chronic pain. Please print this page as documentation, for submission with your CE certificate.

Kentucky: This activity is designed to satisfy requirements for the use of KASPER, pain management, addiction disorders, or a combination of two (2) or more of those subjects. Please print this page as documentation, for submission with your CE certificate.

Massachusetts: This activity is designed to satisfy all prescriber training requirements according to Massachusetts General Law, Chapter 94C, Section 18. Please print this page as documentation, for submission with your CE certificate.

Texas: This activity is approved for Pain Management and Prescription of Opioids requirements from the Texas Medical Board/Board of Nursing, as well as Medical Ethics and/or Professional Responsibility.

Tennessee: This activity is designed to satisfy requirements related to controlled substance prescribing, which must include instruction in the Department’s Pain Management Guidelines on opioids, benzodiazepines, barbiturates and carisoprodol and may include topics such as medicine addiction, risk management tools and other topics approved by the Board. Continuing Education for controlled substance prescribing. 

This activity satisfies training requirements for the MATE Act, which requires all DEA-registered practitioners to complete 8 hours of CME/CE credit on opioid or other substance use disorders. Please visit https://www.pri-med.com/state/mate-act-cme for more information about the MATE Act.

Looking for more mental health CME?

Enroll in Mental Health Bootcamp, an on-demand curriculum with over 30 courses, a library of downloadable resources, and Q&A with faculty.  

Learn More

Faculty

Charles E. Argoff, MD, FABPM

Vice Chair
Professor of Neurology and Urology
Albany Medical College
Director, Comprehensive Pain Center
Director, Pain Management Fellowship
Albany Medical Center
Albany, New York

 
Learn More

Oscar A. de Leon-Casasola, MD

Professor of Anesthesiology and Medicine 
Senior Vice-Chair 
School of Medicine and Biomedical Sciences
University at Buffalo 
Chief, Pain Medicine and Professor of Oncology 
Roswell Park Cancer Institute
Buffalo, New York

Learn More

Katherine E. Galluzzi, DO, CMD, FACOFP

Professor and Chair
Department of Geriatric and Palliative Medicine
Director, Comprehensive Care
Philadelphia College of Osteopathic Medicine
Philadelphia, Pennsylvania

 
Learn More

Disclosures

The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.

Charles E. Argoff, MD, FABPM: 
Speaker’s bureau: AbbVie, Amgen, Averitas Pharma, Biohaven, Grunenthal, Impel Pharmaceuticals, Kowa Pharmaceuticals America, Lilly, Lundbeck, Nevro, and Teva. 
Advisory Board: AbbVie, Amgen, Averitas Pharma, Clexio Biosciences, EnZen Therapeutics, Kowa, Lundbeck, Nevro, Tremeau Pharmaceuticals, Tris Pharma, Vertex and Xgene Pharma. 
Consultant: Neumentum, PainScripts, and Tris Pharma. 
Researcher: AbbVie, Amgen, Lilly, Lundbeck, and Teva. 
Stock Holder: Pfizer and Trevena.

Oscar A. de Leon-Casasola, MD:  Advisory Board and Consultant: Kowa Pharmaceuticals.

Katherine E. Galluzzi, DO, CMD, FACOF:  No relevant financial relationships have been disclosed. 

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

CME Information

AMA PRA Category 1 Credits™

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians. 

Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

Accreditation Statement

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider Number 040308. 

 

Designation Statement

This activity is approved for 1.11 contact hours of continuing education, which includes 0.69 hour of pharmacology.

MOC Credit Information

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Instructions for Obtaining Credit

Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 4 out of the 5 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen. For PAs, the NCCPA accepts for Category 1 CME credit activities designated for AMA PRA Category 1 Credit.

Commercial Supporter

Opioid Analgesic REMS Program Companies

Education Partner

Miller Medical Communications, LLC

Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.

Part 3: Approaches to Opioid Treatment and Counseling Patients

Begin